The early diagnosis, treatment and prevention of cancer recurrence are the major priorities in future oncology. An increasing number of cases are surgically cured as a result of early diagnosis and novel approaches to chemo and radiotherapy. However, a significant percentage of these patients will develop recurrent and/or metastatic disease. The prognosis for patients with metastatic breast, lung and colorectal cancers at diagnosis or as a cancer recurrence are poor.